These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1039 related items for PubMed ID: 27038847

  • 41. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV, Filippatos TD, Elisaf MS.
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [Abstract] [Full Text] [Related]

  • 42. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ.
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL, Degeeter M, Nuzum DS, Tzefos M.
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [Abstract] [Full Text] [Related]

  • 50. The safety of gliptins : updated data in 2018.
    Scheen AJ.
    Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
    [Abstract] [Full Text] [Related]

  • 51. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB.
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Alogliptin benzoate for the treatment of type 2 diabetes.
    Seino Y, Yabe D.
    Expert Opin Pharmacother; 2014 Apr; 15(6):851-63. PubMed ID: 24646052
    [Abstract] [Full Text] [Related]

  • 57. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P, Dhanaraj SA.
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [Abstract] [Full Text] [Related]

  • 58. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V.
    Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
    [Abstract] [Full Text] [Related]

  • 59. Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
    Ryan G.
    Postgrad Med; 2015 Jul; 127(8):842-54. PubMed ID: 26436470
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.